Skip to main content
Premium Trial:

Request an Annual Quote

New Products: CTGT's Connective Tissue Disorder Tests

Premium

Connective Tissue Gene Tests, or CTGT, this week announced the availability of 33 new tests using its next-generation sequencing and microarray technologies.

Twenty of the new panels can be run on its High-Density Targeted Array platform, an Agilent Technologies-manufactured chip for copy number variation detection.

These include tests for genes associated with different types of spondylocostal dysotosis, Norrie disease, pseudoxanthoma elasticum, serpentine fibula-polycystic kidney syndrome, Alagille syndrome, arterial calcification, cleidocranial dysplasia, Ehlers-Danlos syndrome, exudative vitreoretinopathy, Hajdu-Cheney syndrome, hereditary hemorrhagic telangiectasia, and metaphyseal dysplasia.

The Allentown, Pa.-based company charges $1,190 per first gene tested with the array and $590 per additional genes tested.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.